Using Agenerase. Nutritional considerations affect bioavailability of new P.I.
Tong
C
C
Fenton
M
M
Hall
M
M
D001682:Biological Availability; D002219:Carbamates; D004041:Dietary Fats / Q000008:administration & dosage; D018565:Food-Drug Interactions; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D013449:Sulfonamides / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014810:Vitamin E / Q000008:administration & dosage
D002219:Carbamates; D004041:Dietary Fats; D005663:Furans; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D014810:Vitamin E; C095108:amprenavir